Aknamed
Latest, 12 Oct: PharmEasy parent API Holdings cuts FY26 loss 67% to ₹520 Cr as operating revenue grows 12.7%.
Newest on Aknamed
Browse all 5 storiesWhat we know
From 5 stories, the newest dated 12 Oct 2026. Summary written 14 Oct 2026.
Aknamed is associated with API Holdings, the parent of online pharmacy PharmEasy.[1] source: Inc42[2] source: Moneycontrol API Holdings holds Thyrocare through Docon Technologies, which retains a 51.02% stake in Thyrocare.[3] source: The Hindu BusinessLine
API Holdings cut its FY26 consolidated net loss by 67% to ₹520 Cr from ₹1,572 Cr, while operating revenue grew 12.7% to ₹6,618.5 Cr, Inc42 reported in October 2026.[1] source: Inc42 Q1 FY27 revenue rose 10% to ₹1,754 Cr with EBITDA of ₹39.3 Cr.[1] source: Inc42 In August 2026 it repaid ₹1,050 crore of term debt using Thyrocare stake-sale proceeds and internal accruals.[3] source: The Hindu BusinessLine In that sale, 9.90% of Thyrocare's paid-up equity was sold.[3] source: The Hindu BusinessLine In May 2026 it withdrew its Rs 6,250 crore DRHP, which was filed with SEBI in 2021.[2] source: Moneycontrol Forbes India reported in August 2026 a proposed Rs 2,400 crore rights issue.[4] source: Forbes India
ET Retail reported in August 2026 that Ranjan Pai, TPG and Temasek may invest in the ₹2,400 crore rights issue.[5] source: ET Retail
Aknamed has appeared in 5 distinct RetailIntel stories between May 2026 and Oct 2026, most often under retail company and most frequently linked to Ahmedabad and Mumbai.
Brands most often mentioned alongside Aknamed
API Holdings, PharmEasy, Thyrocare, TPG, Ascent, BYJU'S.
Most-cited sources on Aknamed
ET Retail (1 story), Forbes India (1 story) and Inc42 (1 story).